市場調查報告書

胃輕癱的流行病學預測 2028年

Gastroparesis Epidemiology Forecast - 2028

出版商 DelveInsight Business Research LLP 商品編碼 524499
出版日期 內容資訊 英文 100 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
胃輕癱的流行病學預測 2028年 Gastroparesis Epidemiology Forecast - 2028
出版日期: 2019年12月01日內容資訊: 英文 100 Pages
簡介

主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的胃輕癱的總患病數在2017年估算為3369萬400人。

本報告提供主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的胃輕癱市場調查,市場及疾病概要,整體及各國流行病學的預測,性別、年齡、病型的患病數及診斷數的變化與預測,未滿足需求,成長要素及障礙分析等相關資訊彙整。

目錄

第1章 重要洞察

第2章 胃輕癱:患者概要

  • 患者的分佈情形(實在數值)
  • 患者的分佈情形(預測值)

第3章 疾病背景和概要:胃輕癱

  • 原因
    • 特發性胃輕癱(IG)
    • 糖尿病性胃輕癱(DGp)
    • 醫平原性及術後胃輕癱
  • 臨床症狀
  • 機制和病理生理學
  • 診斷

第4章 流行病學和患者人口

  • 主要調查結果
  • 主要7個國家的胃輕癱的總患病數
  • 主要7個國家的胃輕癱的患病數:各類型
  • 主要7個國家的胃輕癱的患病數:性別
  • 主要7個國家的胃輕癱的患病數:各重症度
  • 主要7個國家的胃輕癱的診斷患病數

第5章 美國的胃輕癱的流行病學

  • 假設和理論的根據
  • 主要7個國家的胃輕癱的總患病數
  • 主要7個國家的胃輕癱的患病數:各類型
  • 主要7個國家的胃輕癱的患病數:性別
  • 主要7個國家的胃輕癱的患病數:各重症度
  • 主要7個國家的胃輕癱的診斷患病數

第6章 歐盟5國的胃輕癱的流行病學

  • 德國
    • 假設和理論的根據
    • 胃輕癱的總患病數
    • 胃輕癱的患病數:各類型
    • 胃輕癱的患病數:性別
    • 胃輕癱的患病數:各重症度
    • 胃輕癱的診斷患病數
  • 法國
    • 假設和理論的根據
    • 胃輕癱的總患病數
    • 胃輕癱的患病數:各類型
    • 胃輕癱的患病數:性別
    • 胃輕癱的患病數:各重症度
    • 胃輕癱的診斷患病數
  • 義大利
    • 假設和理論的根據
    • 胃輕癱的總患病數
    • 胃輕癱的患病數:各類型
    • 胃輕癱的患病數:性別
    • 胃輕癱的患病數:各重症度
    • 胃輕癱的診斷患病數
  • 西班牙
    • 假設和理論的根據
    • 胃輕癱的總患病數
    • 胃輕癱的患病數:各類型
    • 胃輕癱的患病數:性別
    • 胃輕癱的患病數:各重症度
    • 胃輕癱的診斷患病數
  • 英國
    • 假設和理論的根據
    • 胃輕癱的總患病數
    • 胃輕癱的患病數:各類型
    • 胃輕癱的患病數:性別
    • 胃輕癱的患病數:各重症度
    • 胃輕癱的診斷患病數

第7章 日本的胃輕癱的流行病學

  • 假設和理論的根據
  • 胃輕癱的總患病數
  • 胃輕癱的患病數:各類型
  • 胃輕癱的患病數:性別
  • 胃輕癱的患病數:各重症度
  • 胃輕癱的診斷患病數

第8章 治療流程、現行治療、治療行為

  • 治療流程
  • 治療和管理
    • 飲食的變更
    • 藥理學性治療
    • 幽門介入
    • 胃的電刺激

第9章 胃輕癱管理的臨床指南

  • 建議
  • 糖尿病性胃輕癱臨床管理的共識指南

第10章 未滿足需求

第11章 已上市醫藥品

  • Reglan:ANI Pharmaceuticals
    • 產品概要
    • 法規里程碑
    • 產品簡介
  • Motilium (Domperidone):Janssen

第12章 新藥

  • Key Cross Competition
  • Relamorelin:Allergan
    • 產品概要
    • 開發趨勢
    • 臨床趨勢
    • 產品簡介
  • Gimoti (Metoclopramide Nasal Spray):Evoke Pharma
  • Tradipitant:Vanda Pharmaceuticals
  • Velusetrag:Theravance Biopharma
  • CNSA-001:Censa Pharmaceuticals
  • Nimacimab:Bird Rock Bio
  • CIN-102:CinDome Pharma
  • TAK 906:武田藥品

第13章 市場分析主要7個國家

  • 主要調查結果
  • 主要7個國家的胃輕癱的市場規模
  • 主要7個國家的胃輕癱的市場規模:各治療藥物

第14章 美國市場預測

  • 美國的胃輕癱的市場規模
    • 整體市場規模
    • 市場規模:各治療藥物

第15章 市場預測歐洲5個國家

  • 德國的胃輕癱的市場規模
    • 整體市場規模
    • 市場規模:各治療藥物
  • 法國的胃輕癱的市場規模
    • 整體市場規模
    • 市場規模:各治療藥物
  • 義大利的胃輕癱的市場規模
    • 整體市場規模
    • 市場規模:各治療藥物
  • 西班牙的胃輕癱的市場規模
    • 整體市場規模
    • 市場規模:各治療藥物
  • 英國的胃輕癱的市場規模
    • 整體市場規模
    • 市場規模:各治療藥物

第16章 日本市場預測

  • 日本的胃輕癱的市場規模
    • 整體市場規模
    • 市場規模:各治療藥物

第17章 市場成長要素

第18章 市場障礙

第19章 附錄

  • 調查方法

第20章 DelveInsight的服務內容

第21章 免責聲明

第22章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIEI0085

DelveInsight's Gastroparesis Epidemiology Forecast to 2028 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Gastroparesis in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

Gastroparesis - Disease Understanding and Treatment Algorithm

Gastroparesis, which is a translated meaning of "stomach paralysis", is a digestive disorder characterized by delayed gastric emptying of solid food in the absence of mechanical obstruction of the stomach, resulting in the cardinal symptoms of early satiety, postprandial fullness, nausea, vomiting, belching and bloating. It is now recognized as part of a broader spectrum of gastric neuromuscular dysfunction that includes impaired gastric accommodation. The overlap between the symptoms, of Gastroparesis and other disorders such as functional dyspepsia, makes the diagnosis of Gastroparesis difficult.

Gastroparesis may be idiopathic or associated with diabetes mellitus, may occur after a medical intervention (iatrogenic or post-surgical), or with neurological disorders, it can also occur after a viral or bacterial infection, such as Salmonella gastroenteritis. Interestingly, Helicobacter pylori infection of the stomach does not seem to influence gastric emptying or accommodation but may be associated with heightened sensitivity in patients with functional dyspepsia.

"According to the American Diabetes Association, Gastroparesis is a disorder affecting people with both type 1 and type 2 diabetes, in which the stomach takes too long to empty its contents (delayed gastric emptying). The vagus nerve controls the movement of food through the digestive tract. If this nerve is damaged or stops working, the muscles of the stomach and intestines do not work normally, and the movement of food is slowed or stopped. Just as with other types of neuropathy, diabetes can damage the vagus nerve if blood glucose levels remain high over a long period. High blood glucose causes chemical changes in nerves and damages the blood vessels that carry oxygen and nutrients to the nerves."

The etiology of Gastroparesis include diabetic, postsurgical, Iatrogenic, surgical and idiopathic as these are major causes of gastroparesis. Based on the causes, Gastroparesis is divided into three major types, i.e., Idiopathic gastroparesis, Diabetic gastroparesis, and Post-surgical gastroparesis. Some of the researchers proposed a classification system to help determine appropriate treatment options such as Grade 1, or mild gastroparesis, is characterized by symptoms that come and go and can easily be controlled by dietary modification and by avoiding medications that slow gastric emptying. Grade 2, or compensated gastroparesis, is characterized by moderately severe symptoms.

DelveInsight's Gastroparesis epidemiology report gives a thorough understanding of the Gastroparesis by including details, such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends.

Gastroparesis-Epidemiology

The Gastroparesis epidemiology division provides insights about historical and current patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders (KOL). This part of the DelveInsight's report also provides the diagnosed patient pool and their trends along with undertaken assumptions.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Prevalence of Gastroparesis, Gender-Specific Prevalence of Gastroparesis, Severity-Specific Prevalence of Gastroparesis, Type-Specific Prevalence of Gastroparesis, and Total Diagnosed Prevalent Population of Gastroparesis] scenario of Gastroparesis in the 7MM Countries covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2028.

DelveInsight's analysts have assessed that the total prevalent population of Gastroparesis in the 7MM was 33,690,400 in 2017. Additionally, it was accessed that the total diagnosed prevalent population of Gastroparesis in the 7MM was assessed to be 16,845,200 in 2017. DelveInsight's estimate suggests that the United States witnessed the highest number of cases with Gastroparesis, as compared to other 7MM countries. As per DelveInsight's estimates, the country accounted for approximately 13,019,321 cases in 2017. Among the European 5 countries, Germany had the highest prevalent population of Gastroparesis, followed by Spain and Italy. On the other hand, the United Kingdom had the lowest prevalent population of Gastroparesis in 2017. Furthermore, Japan had 5,785,669 prevalent cases for Gastroparesis in 2017. As per DelveInsight's analysis, a higher percentage of diagnosed prevalence of Gastroparesis was observed for females, in comparison to males, in all the 7MM countries.

Report Scope

  • The report covers a detailed overview of Gastroparesis explaining its causes, symptoms, classification, and pathophysiology.
  • The report provides insight about the historical and forecasted patient pool for seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan.
  • The report helps to recognize the growth opportunities in the 7MM countries with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology by Total Prevalence of Gastroparesis in the 7MM, Gender-Specific Prevalence of Gastroparesis, Severity-Specific Diagnosed Prevalence of Gastroparesis, Type-Specific Diagnosed Prevalence of Gastroparesis, and Total Diagnosed Prevalent Population of Gastroparesis

Gastroparesis Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Total Prevalence of Gastroparesis
  • Gender-Specific Prevalence of Gastroparesis
  • Severity-Specific Prevalence of Gastroparesis
  • Type-Specific Prevalence of Gastroparesis
  • Total Diagnosed Prevalent Population of Gastroparesis

Gastroparesis Report Assessment

  • Patient segmentation
  • Disease risk and burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Gastroparesis: Market Overview at a Glance

  • 2.1. Total Market Share (%) Distribution of Gastroparesis in 2017
  • 2.2. Total Market Share (%) Distribution of Gastroparesis in 2028

3. Gastroparesis: Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Types of Gastroparesis: Based on Causes
    • 3.2.1. Idiopathic Gastroparesis (IG)
    • 3.2.2. Diabetic Gastroparesis (DGp)
    • 3.2.3. Iatrogenic and Postsurgical Gastroparesis
  • 3.3. Clinical Signs and Symptoms
  • 3.4. Mechanisms or Pathophysiology of Gastroparesis
  • 3.5. Diagnosis of Gastroparesis

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Total Prevalence of Gastroparesis in the 7MM
  • 4.3. Type-Specific Prevalence of Gastroparesis in the 7MM
  • 4.4. Gender-Specific Prevalence of Gastroparesis in the 7MM
  • 4.5. Severity Specific Prevalence of Gastroparesis in the 7MM
  • 4.6. Total Diagnosed Prevalent Population of Gastroparesis in the 7MM

5. United States Epidemiology

  • 5.1. Assumptions and Rationale
  • 5.2. Total Prevalence of Gastroparesis in the United States
  • 5.3. Type-Specific Diagnosed Prevalence of Gastroparesis in the United States
  • 5.4. Gender-Specific Prevalence of Gastroparesis in the United States
  • 5.5. Severity Specific Prevalence of Gastroparesis in the United States
  • 5.6. Total Diagnosed Prevalence of Gastroparesis in the United States

6. EU5 Epidemiology

  • 6.1. Germany Epidemiology
    • 6.1.1. Total Prevalence of Gastroparesis in Germany
    • 6.1.2. Type-Specific Prevalence of Gastroparesis in Germany
    • 6.1.3. Gender-Specific Prevalence of Gastroparesis in Germany
    • 6.1.4. Severity Specific Prevalence of Gastroparesis in Germany
    • 6.1.5. Total Diagnosed Prevalence of Gastroparesis in Germany
  • 6.2. France Epidemiology
    • 6.2.1. Total Prevalence of Gastroparesis in France
    • 6.2.2. Type-Specific Prevalence of Gastroparesis in France
    • 6.2.3. Gender-Specific Prevalence of Gastroparesis in France
    • 6.2.4. Severity Specific Prevalence of Gastroparesis in France
    • 6.2.5. Total Diagnosed Prevalence of Gastroparesis in France
  • 6.3. Italy Epidemiology
    • 6.3.1. Total Prevalence of Gastroparesis in Italy
    • 6.3.2. Type-Specific Prevalence of Gastroparesis in Italy
    • 6.3.3. Gender-Specific Prevalence of Gastroparesis in Italy
    • 6.3.4. Severity Specific Prevalence of Gastroparesis in Italy
    • 6.3.5. Total Diagnosed Prevalence of Gastroparesis in Italy
  • 6.4. Spain Epidemiology
    • 6.4.1. Total Prevalence of Gastroparesis in Spain
    • 6.4.2. Type-Specific Prevalence of Gastroparesis in Spain
    • 6.4.3. Gender-Specific Prevalence of Gastroparesis in Spain
    • 6.4.4. Severity Specific Prevalence of Gastroparesis in Spain
    • 6.4.5. Total Diagnosed Prevalence of Gastroparesis in Spain
  • 6.5. United Kingdom Epidemiology
    • 6.5.1. Total Prevalence of Gastroparesis in the United Kingdom
    • 6.5.2. Type-Specific Prevalence of Gastroparesis in the United Kingdom
    • 6.5.3. Gender-Specific Prevalence of Gastroparesis in the United Kingdom
    • 6.5.4. Severity Specific Prevalence of Gastroparesis in the United Kingdom
    • 6.5.5. Total Diagnosed Prevalence of Gastroparesis in the United Kingdom

7. Japan Epidemiology

  • 7.1. Assumptions and Rationale
  • 7.2. Total Prevalence of Gastroparesis in Japan
  • 7.3. Type-Specific Prevalence of Gastroparesis in Japan
  • 7.4. Gender-Specific Prevalence of Gastroparesis in Japan
  • 7.5. Severity Specific Prevalence of Gastroparesis in Japan
  • 7.6. Total Diagnosed Prevalence of Gastroparesis in Japan

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Treatment Algorithm for Gastroparesis
  • 8.2. Treatment and Management for Gastroparesis
    • 8.2.1. Dietary Modifications
    • 8.2.2. Pharmacological Treatment
    • 8.2.3. Pyloric Intervention
    • 8.2.4. Gastric Electrical Stimulation

9. Proposed Clinical Guidelines for the Management of Gastroparesis

  • 9.1. Recommendations
  • 9.2. Consensus Guidelines for Clinical Management of Diabetic Gastroparesis

10. Unmet Needs

11. Marketed Products

  • 11.1. Reglan: ANI Pharmaceuticals
    • 11.1.1. Product Description
    • 11.1.2. Regulatory Milestones
    • 11.1.3. Product Profile
  • 11.2. Motilium (Domperidone): Janssen
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Safety and Efficacy
    • 11.2.4. Product Profile

12. Emerging Therapies

  • 12.1. Key Cross Competition
  • 12.2. Relamorelin: Allergan
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Product Profile
  • 12.3. Gimoti (Metoclopramide Nasal Spray): Evoke Pharma
    • 12.3.1. Product Description
    • 12.3.2. Other Developmental Activities
    • 12.3.3. Clinical Development
    • 12.3.4. Safety and Efficacy
    • 12.3.5. Product Profile
  • 12.4. Tradipitant: Vanda Pharmaceuticals
    • 12.4.1. Product Description
    • 12.4.2. Other Developmental Activities
    • 12.4.3. Clinical Development
    • 12.4.4. Safety and Efficacy
    • 12.4.5. Product Profile
  • 12.5. Velusetrag: Theravance Biopharma
    • 12.5.1. Product Description
    • 12.5.2. Other Developmental Activities
    • 12.5.3. Clinical Development
    • 12.5.4. Safety and Efficacy
    • 12.5.5. Product Profile
  • 12.6. CNSA-001: Censa Pharmaceuticals
    • 12.6.1. Product Description
    • 12.6.2. Clinical Development
    • 12.6.3. Product Profile
  • 12.7. Nimacimab: Bird Rock Bio
    • 12.7.1. Product Description
    • 12.7.2. Other Development Activities
    • 12.7.3. Clinical Development
    • 12.7.4. Product Profile
  • 12.8. CIN-102: CinDome Pharma
    • 12.8.1. Product Description
    • 12.8.2. Other Developmental Activities
    • 12.8.3. Clinical Development
    • 12.8.4. Safety and Efficacy
    • 12.8.5. Product Profile
  • 12.9. TAK 906: Takeda (Millennium Pharmaceuticals)
    • 12.9.1. Product Description
    • 12.9.2. Other Developmental Activities
    • 12.9.3. Clinical Development
    • 12.9.4. Safety and Efficacy
    • 12.9.5. Product Profile

13. Gastroparesis: Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Market Size of Gastroparesis in 7MM
  • 13.3. Market Size of Gastroparesis by Therapies in the 7MM

14. United States: Market Outlook

  • 14.1. United States Market Size
    • 14.1.1. Total Market size of Gastroparesis in the United States
    • 14.1.2. Market Size of Gastroparesis by Therapies in the US

15. EU-5 countries: Market Outlook

  • 15.1. Germany Market Size
    • 15.1.1. Total Market size of Gastroparesis in Germany
    • 15.1.2. Market Size of Gastroparesis by therapies in Germany
  • 15.2. France Market Size
    • 15.2.1. Total Market size of Gastroparesis in France
    • 15.2.2. Market Size of Gastroparesis by therapies in France
  • 15.3. Italy Market Size
    • 15.3.1. Total Market size of Gastroparesis in Italy
    • 15.3.2. Market Size of Gastroparesis by therapies in Italy
  • 15.4. Spain Market Size
    • 15.4.1. Total Market size of Gastroparesis in Spain
    • 15.4.2. Market Size of Gastroparesis by therapies in Spain
  • 15.5. United Kingdom Market Size
    • 15.5.1. Total Market size of Gastroparesis in the United Kingdom
    • 15.5.2. Market Size of Gastroparesis by therapies in the UK

16. Japan Market Outlook

  • 16.1. Japan Market Size
    • 16.1.1. Total Market size of Gastroparesis in Japan
    • 16.1.2. Market Size of Gastroparesis by therapies in Japan

17. Market Drivers

18. Market Barriers

19. Appendix

  • 19.1. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

List of Tables

  • Table 1 Pathogenesis and Etiology of Gastroparesis
  • Table 2 Total Prevalence of Gastroparesis in the 7MM (2017-2028)
  • Table 3 Type-Specific Prevalence of Gastroparesis in the 7MM (2017-2028)
  • Table 4 Gender-Specific Prevalence of Gastroparesis in the 7MM (2017-2028)
  • Table 5 Severity-Specific Prevalence of Gastroparesis in the 7MM (2017-2028)
  • Table 6 Total Diagnosed Prevalent Population of Gastroparesis in the 7MM (2017-2028)
  • Table 7 Total Prevalence of Gastroparesis in the United States (2017-2028)
  • Table 8 Type-Specific Diagnosed Prevalence of Gastroparesis in the United States (2017-2028)
  • Table 9 Gender-Specific Prevalence of Gastroparesis in the US (2017-2028)
  • Table 10 Severity-Specific Prevalence of Gastroparesis in the United States(2017-2028)
  • Table 11 Total Diagnosed Prevalence of Gastroparesis in the United States (2017-2028)
  • Table 12 Total Prevalence of Gastroparesis in Germany (2017-2028)
  • Table 13 Type-Specific Prevalence of Gastroparesis in Germany (2017-2028)
  • Table 14 Gender-Specific Prevalence of Gastroparesis in Germany (2017-2028)
  • Table 15 Severity-Specific Prevalence of Gastroparesis in Germany (2017-2028)
  • Table 16 Total Diagnosed Prevalence of Gastroparesis in Germany (2017-2028)
  • Table 17 Total Prevalence of Gastroparesis in France (2017-2028)
  • Table 18 Type-Specific Prevalence of Gastroparesis in France (2017-2028)
  • Table 19 Gender-Specific Prevalence of Gastroparesis in France (2017-2028)
  • Table 20 Severity-Specific Prevalence of Gastroparesis in France (2017-2028)
  • Table 21 Total Diagnosed Prevalence of Gastroparesis in France (2017-2028)
  • Table 22 Total Prevalence of Gastroparesis in Italy (2017-2028)
  • Table 23 Type-Specific Prevalence of Gastroparesis in Italy (2017-2028)
  • Table 24 Gender-Specific Prevalence of Gastroparesis in Italy (2017-2028)
  • Table 25 Severity-Specific Prevalence of Gastroparesis in Italy (2017-2028)
  • Table 26 Total Diagnosed Prevalence of Gastroparesis in Italy (2017-2028)
  • Table 27 Total Prevalence of Gastroparesis in Spain (2017-2028)
  • Table 28 Type-Specific Prevalence of Gastroparesis in Spain (2017-2028)
  • Table 29 Gender-Specific Prevalence of Gastroparesis in Spain (2017-2028)
  • Table 30 Severity-Specific Prevalence of Gastroparesis in Spain (2017-2028)
  • Table 31 Total Diagnosed Prevalence of Gastroparesis in Spain (2017-2028)
  • Table 32 Total Prevalence of Gastroparesis in the United Kingdom (2017-2028)
  • Table 33 Type-Specific Prevalence of Gastroparesis in the United Kingdom (2017-2028)
  • Table 34 Gender-Specific Prevalence of Gastroparesis in the United Kingdom (2017-2028)
  • Table 35 Severity-Specific Prevalence of Gastroparesis in the United Kingdom (2017-2028)
  • Table 36 Total Diagnosed Prevalence of Gastroparesis in the United Kingdom (2017-2028)
  • Table 37 Total Prevalence of Gastroparesis in Japan (2017-2028)
  • Table 38 Type-Specific Prevalence of Gastroparesis in Japan (2017-2028)
  • Table 39 Gender-Specific Prevalence of Gastroparesis in Japan (2017-2028)
  • Table 40 Severity-Specific Prevalence of Gastroparesis in Japan (2017-2028)
  • Table 41 Total Diagnosed Prevalence of Gastroparesis in Japan (2017-2028)
  • Table 42 Pharmacological Treatment Options for the Management of Diabetic Gastroparesis
  • Table 43 Pharmacological Treatment Options for the Management of Diabetic Gastroparesis
  • Table 44 Pharmacological Treatment Options for the Management of Diabetic Gastroparesis
  • Table 45 Emerging Keycross Competition
  • Table 46 Relamorelin (RM-131), Clinical Trial Description, 2019
  • Table 47 Metoclopramide Nasal Spray; Clinical Trial Description, 2019
  • Table 48 Tradipitant; Clinical Trial Description, 2019
  • Table 49 Velusetrag; Clinical Trial Description, 2019
  • Table 50 CNSA-001, Clinical Trial Description, 2019
  • Table 51 Nimacimab, Clinical Trial Description, 2019
  • Table 52 CIN-102, Clinical Trial Description, 2019
  • Table 53 TAK 906, Clinical Trial Description, 2019
  • Table 54 Market Size of Gastroparesis in 7MM in USD Million (2017-2028)
  • Table 55 Market Size of Gastroparesis by therapies in the 7MM, in USD Million (2017-2028)
  • Table 56 Currently Prescribed Classes and their Side-Effects
  • Table 57 Emerging Therapies Expected to be Launched During Forecast Period (2019-2028) in the United States
  • Table 58 The US Market Size of Gastroparesis in USD Million (2017-2028)
  • Table 59 Market Size of Gastroparesis by therapies in the US, in USD Million (2017-2028)
  • Table 60 Germany Market Size of Gastroparesis in USD Million (2017-2028)
  • Table 61 Market Size of Gastroparesis by therapies in Germany, in USD Million (2017-2028)
  • Table 62 France Market Size of Gastroparesis in USD Million (2017-2028)
  • Table 63 Market Size of Gastroparesis by therapies in France, in USD Million (2017-2028)
  • Table 64 Italy Market Size of Gastroparesis in USD Million (2017-2028)
  • Table 65 Market Size of Gastroparesis by therapies in Italy, in USD Million (2017-2028)
  • Table 66 Spain Market Size of Gastroparesis in USD Million (2017-2028)
  • Table 67 Market Size of Gastroparesis by therapies in Spain, in USD Million (2017-2028)
  • Table 68 The UK Market Size of Gastroparesis in USD Million (2017-2028)
  • Table 69 Market Size of Gastroparesis by therapies in the UK, in USD Million (2017-2028)
  • Table 70 Japan Market Size of Gastroparesis in USD Million (2017-2028)
  • Table 71 Market Size of Gastroparesis by therapies in Japan, in USD Million (2017-2028)

List of Figures

  • Figure 1 Types of Gastroparesis Based on Causes
  • Figure 2 Etiologies of Gastroparesis
  • Figure 3 Interaction of Interstitial Cells of Cajal (ICC) Cells and Neuronal Nitric Oxide Synthase (nNOS) Signaling for Normal Gastric Emptying (GE)
  • Figure 4 Mechanisms of Gastric Accommodation and Emptying
  • Figure 5 Diagnosis of Gastroparesis
  • Figure 6 Total Prevalence of Gastroparesis in the 7MM (2017-2028)
  • Figure 7 Type-Specific Prevalence of Gastroparesis in the 7MM (2017-2028)
  • Figure 8 Gender- Specific Prevalence of Gastroparesis in the 7MM(2017-2028)
  • Figure 9 Severity-Specific Prevalence of Gastroparesis in the 7MM (2017-2028)
  • Figure 10 Total Diagnosed Prevalent Population of Gastroparesis in the 7MM (2017-2028)
  • Figure 11 Total Prevalence of Gastroparesis in the United States (2017-2028)
  • Figure 12 Type-Specific Diagnosed Prevalence of Gastroparesis in the United States (2017-2028)
  • Figure 13 Gender- Specific Prevalence of Gastroparesisin the US (2017-2028)
  • Figure 14 Severity-Specific Prevalence of Gastroparesis in the United States (2017-2028)
  • Figure 15 Total Diagnosed Prevalence of Gastroparesis in the United States (2017-2028)
  • Figure 16 Total Prevalence of Gastroparesis in Germany (2017-2028)
  • Figure 17 Type-Specific Prevalence of Gastroparesis in Germany (2017-2028)
  • Figure 18 Gender- Specific Prevalence of Gastroparesis in Germany (2017-2028)
  • Figure 19 Severity-Specific Prevalence of Gastroparesis in Germany (2017-2028)
  • Figure 20 Total Diagnosed Prevalence of Gastroparesis in Germany (2017-2028)
  • Figure 21 Total Prevalence of Gastroparesis in France (2017-2028)
  • Figure 22 Type-Specific Prevalence of Gastroparesis in France (2017-2028)
  • Figure 23 Gender- Specific Prevalence of Gastroparesis in France (2017-2028)
  • Figure 24 Severity-Specific Prevalence of Gastroparesis in France (2017-2028)
  • Figure 25 Total Diagnosed Prevalence of Gastroparesis in France (2017-2028)
  • Figure 26 Total Prevalence of Gastroparesis in Italy (2017-2028)
  • Figure 27 Type-Specific Prevalence of Gastroparesis in Italy (2017-2028)
  • Figure 28 Gender- Specific Prevalence of Gastroparesis in Italy (2017-2028)
  • Figure 29 Severity-Specific Prevalence of Gastroparesis in Italy (2017-2028)
  • Figure 30 Total Diagnosed Prevalence of Gastroparesis in Italy (2017-2028)
  • Figure 31 Total Prevalence of Gastroparesis in Spain (2017-2028)
  • Figure 32 Type-Specific Prevalence of Gastroparesis in Spain (2017-2028)
  • Figure 33 Gender- Specific Prevalence of Gastroparesis in Spain (2017-2028)
  • Figure 34 Severity-Specific Prevalence of Gastroparesis in Spain (2017-2028)
  • Figure 35 Total Diagnosed Prevalence of Gastroparesis in Spain (2017-2028)
  • Figure 36 Total Prevalence of Gastroparesis in the United Kingdom (2017-2028)
  • Figure 37 Type-Specific Prevalence of Gastroparesis in the United Kingdom (2017-2028)
  • Figure 38 Gender- Specific Prevalence of Gastroparesis in the United Kingdom (2017-2028)
  • Figure 39 Severity-Specific Prevalence of Gastroparesis in the United Kingdom (2017-2028)
  • Figure 40 Total Diagnosed Prevalence of Gastroparesis in the United Kingdom (2017-2028)
  • Figure 41 Total Prevalence of Gastroparesis in Japan (2017-2028)
  • Figure 42 Type-Specific Prevalence of Gastroparesis in Japan (2017-2028)
  • Figure 43 Gender- Specific Prevalence of Gastroparesis in Japan (2017-2028)
  • Figure 44 Severity-Specific Prevalence of Gastroparesis in Japan (2017-2028)
  • Figure 45 Total Diagnosed Prevalence of Gastroparesis in Japan (2017-2028)
  • Figure 46 Diagnosis and Management Algorithm for Gastroparesis Syndromes
  • Figure 47 Algorithm for Prokinetic Therapy in Gastroparesis
  • Figure 48 Treatment Algorithm for Gastroparesis
  • Figure 49 Unmet Needs of Gastroparesis
  • Figure 50 Potential Drug-drug Interactions in Gastroparesis
  • Figure 51 Market Size of Gastroparesis in the 7MM in USD Million (2017-2028)
  • Figure 52 Market Size of Gastroparesis by therapies in the 7MM, in USD Million (2017-2028)
  • Figure 53 Market Size of Gastroparesis in the US, USD Millions (2017-2028)
  • Figure 54 Market Size of Gastroparesis by therapies in the United States, in USD Million (2017-2028)
  • Figure 55 Market Size of Gastroparesis in Germany, USD Millions (2017-2028)
  • Figure 56 Market Size of Gastroparesis by therapies in Germany, in USD Million (2017-2028)
  • Figure 57 Market Size of Gastroparesis in France, USD Millions (2017-2028)
  • Figure 58 Market Size of Gastroparesis by therapies in France, in USD Million (2017-2028)
  • Figure 59 Market Size of Gastroparesis in Italy, USD Millions (2017-2028)
  • Figure 60 Market Size of Gastroparesis by therapies in Italy in USD Million (2017-2028)
  • Figure 61 Market Size of Gastroparesis in Spain, USD Millions (2017-2028)
  • Figure 62 Market Size of Gastroparesis by therapies in Spain in USD Million (2017-2028)
  • Figure 63 Market Size of Gastroparesis in the UK, USD Millions (2017-2028)
  • Figure 64 Market Size of Gastroparesis by therapies in the UK in USD Million (2017-2028)
  • Figure 65 Market Size of Gastroparesis in Japan, USD Millions (2017-2028)
  • Figure 66 Market Size of Gastroparesis by therapies in Japan in USD Million (2017-2028)
  • Figure 67 Market Drivers
  • Figure 68 Market Barriers
Back to Top